131 related articles for article (PubMed ID: 38175451)
21. Reactivation of resolved hepatitis B virus infection combined with nephrotic syndrome in a patient after allogeneic haematopoietic stem cell transplantation.
Zhang JW; Zhang XZ; Sun YL; Long B; Wang XZ; Li XD
BMC Infect Dis; 2019 Jan; 19(1):57. PubMed ID: 30651070
[TBL] [Abstract][Full Text] [Related]
22. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection.
Lai CL; Rosmawati M; Lao J; Van Vlierberghe H; Anderson FH; Thomas N; Dehertogh D
Gastroenterology; 2002 Dec; 123(6):1831-8. PubMed ID: 12454840
[TBL] [Abstract][Full Text] [Related]
23. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks.
Sherman M; Yurdaydin C; Simsek H; Silva M; Liaw YF; Rustgi VK; Sette H; Tsai N; Tenney DJ; Vaughan J; Kreter B; Hindes R;
Hepatology; 2008 Jul; 48(1):99-108. PubMed ID: 18537189
[TBL] [Abstract][Full Text] [Related]
24. Complete remission of hepatitis B virus-related membranous nephropathy after entecavir monotherapy.
Yang YF; Xiong QF; Zhao W; Zhong YD
Clin Res Hepatol Gastroenterol; 2012 Oct; 36(5):e89-92. PubMed ID: 22572521
[TBL] [Abstract][Full Text] [Related]
25. Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infection.
Sulkowski MS; Agarwal K; Ma X; Nguyen TT; Schiff ER; Hann HL; Dieterich DT; Nahass RG; Park JS; Chan S; Han SB; Gane EJ; Bennett M; Alves K; Evanchik M; Yan R; Huang Q; Lopatin U; Colonno R; Ma J; Knox SJ; Stamm LM; Bonacini M; Jacobson IM; Ayoub WS; Weilert F; Ravendhran N; Ramji A; Kwo PY; Elkhashab M; Hassanein T; Bae HS; Lalezari JP; Fung SK; Yuen MF
J Hepatol; 2022 Nov; 77(5):1265-1275. PubMed ID: 35697332
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study.
Liaw YF; Raptopoulou-Gigi M; Cheinquer H; Sarin SK; Tanwandee T; Leung N; Peng CY; Myers RP; Brown RS; Jeffers L; Tsai N; Bialkowska J; Tang S; Beebe S; Cooney E
Hepatology; 2011 Jul; 54(1):91-100. PubMed ID: 21503940
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of entecavir plus carnitine complex (GODEX®) compared to entecavir monotherapy in patient with ALT elevated chronic hepatitis B: randomized, multicenter open-label trials. The GOAL study.
Jun DW; Kim BI; Cho YK; Kim HJ; Kwon YO; Park SY; Han SY; Baek YH; Jung YJ; Kim HY; Kim W; Heo J; Woo HY; Hwang SG; Rim KS; Choi JY; Bae SH; Lee YS; Lim YS; Cheong JY; Cho SW; Lee BS; Kim SH; Sohn JH; Kim TY; Paik YH; Kim JK; Lee KS
Clin Mol Hepatol; 2013 Jun; 19(2):165-72. PubMed ID: 23837141
[TBL] [Abstract][Full Text] [Related]
28. Entecavir: a new nucleoside analog for the treatment of chronic hepatitis B infection.
Sims KA; Woodland AM
Pharmacotherapy; 2006 Dec; 26(12):1745-57. PubMed ID: 17125436
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of entecavir in nucleoside-naive, chronic hepatitis B patients: phase II clinical study in Japan.
Kobashi H; Takaguchi K; Ikeda H; Yokosuka O; Moriyama M; Imazeki F; Kage M; Seriu T; Omata M; Sakaguchi K; Shiratori Y
J Gastroenterol Hepatol; 2009 Feb; 24(2):255-61. PubMed ID: 19215336
[TBL] [Abstract][Full Text] [Related]
30. Seroconversion of hepatitis B envelope antigen by entecavir in a child with hepatitis B virus-related membranous nephropathy.
Igarashi T; Shimizu A; Igarashi T; Hanaoka K; Yoshizaki K; Shigemori T; Shimizu S; Komeichi H; Itoh Y
J Nippon Med Sch; 2013; 80(5):387-95. PubMed ID: 24189358
[TBL] [Abstract][Full Text] [Related]
31. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.
Lai CL; Shouval D; Lok AS; Chang TT; Cheinquer H; Goodman Z; DeHertogh D; Wilber R; Zink RC; Cross A; Colonno R; Fernandes L;
N Engl J Med; 2006 Mar; 354(10):1011-20. PubMed ID: 16525138
[TBL] [Abstract][Full Text] [Related]
32. Analysis of antiviral efficacy after switching from brand to generic entecavir in patients with treatment-naïve chronic hepatitis B.
Hsu PK; Su PY; Wu CL
BMC Gastroenterol; 2022 May; 22(1):228. PubMed ID: 35538425
[TBL] [Abstract][Full Text] [Related]
33. Effectiveness and Safety of Entecavir or Tenofovir in a Spanish Cohort of Chronic Hepatitis B Patients: Validation of the Page-B Score to Predict Hepatocellular Carcinoma.
Riveiro-Barciela M; Tabernero D; Calleja JL; Lens S; Manzano ML; Rodríguez FG; Crespo J; Piqueras B; Pascasio JM; Comas C; Gutierrez ML; Aguirre A; Suárez E; García-Samaniego J; Rivero M; Acero D; Fernandez-Bermejo M; Moreno D; Sánchez-Pobre P; de Cuenca B; Moreno-Palomares JJ; Esteban R; Buti M
Dig Dis Sci; 2017 Mar; 62(3):784-793. PubMed ID: 28078526
[TBL] [Abstract][Full Text] [Related]
34. A comparison of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive patients: a prospective cohort study in China.
Zhang Y; Hu P; Qi X; Ren H; Mao RC; Zhang JM
Clin Microbiol Infect; 2016 Mar; 22(3):287.e1-9. PubMed ID: 26548508
[TBL] [Abstract][Full Text] [Related]
35. Long-term real-world entecavir therapy in treatment-naïve hepatitis B patients: base-line hepatitis B virus DNA and hepatitis B surface antigen levels predict virologic response.
Cho JY; Sohn W; Sinn DH; Gwak GY; Paik YH; Choi MS; Koh KC; Paik SW; Yoo BC; Lee JH
Korean J Intern Med; 2017 Jul; 32(4):636-646. PubMed ID: 27809454
[TBL] [Abstract][Full Text] [Related]
36. Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus-related cirrhosis.
Köklü S; Tuna Y; Gülşen MT; Demir M; Köksal AŞ; Koçkar MC; Aygün C; Coban S; Ozdil K; Ataseven H; Akin E; Pürnak T; Yüksel I; Ataseven H; Ibiş M; Yildirim B; Nadir I; Küçükazman M; Akbal E; Yüksel O; Başar O; Alkan E; Baykal O
Clin Gastroenterol Hepatol; 2013 Jan; 11(1):88-94. PubMed ID: 23063679
[TBL] [Abstract][Full Text] [Related]
37. Retreatment Efficacy and Renal Safety of Tenofovir Alafenamide, Entecavir, and Tenofovir Disoproxil Fumarate After Entecavir or Tenofovir Cessation.
Chiu SM; Chang KC; Hu TH; Hung CH; Wang JH; Lu SN; Chen CH
Dig Dis Sci; 2023 Feb; 68(2):665-675. PubMed ID: 35976597
[TBL] [Abstract][Full Text] [Related]
38. Perioperative entecavir for patients with HBV-related hepatocellular carcinoma and low levels of viral DNA: analysis using propensity score matching.
Yuan BH; Li RH; Yuan WP; Xiang BD; Zheng MH; Yang T; Zhong JH; Li LQ
Oncotarget; 2017 Aug; 8(31):51810-51816. PubMed ID: 28881690
[TBL] [Abstract][Full Text] [Related]
39. Renal safety of tenofovir disoproxil fumarate and entecavir with hepatitis B immunoglobulin in liver transplant patients.
Lee J; Park JY; Yang SJ; Lee JY; Kim DG; Joo DJ; Kim MS; Kim SI; Lee JG
J Viral Hepat; 2020 Aug; 27(8):818-825. PubMed ID: 32302037
[TBL] [Abstract][Full Text] [Related]
40. Comparison of the efficacy of Lamivudine plus adefovir versus entecavir in the treatment of Lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis.
Huang ZB; Zhao SS; Huang Y; Dai XH; Zhou RR; Yi PP; Chen RC; Li WT; Zhang BX; Li N; Fan XG
Clin Ther; 2013 Dec; 35(12):1997-2006. PubMed ID: 24238791
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
